Home Newsfeeds Needham Maintains Buy on NAPCO Security Techs, Raises Price Target to $34

Needham Maintains Buy on NAPCO Security Techs, Raises Price Target to $34

Needham analyst James Ricchiuti maintains NAPCO Security Techs (NASDAQ:NSSC) with a Buy and raises the price target from $33 to $34.

byBenzinga Newsdesk

November 8, 2022

1 minute read

Needham analyst James Ricchiuti maintains NAPCO Security Techs (NASDAQ:NSSC) with a Buy and raises the price target from $33 to $34.

‘Copy Cat:’ Elon Musk Taunts Mark Zuckerberg For Reportedly Planning Twitter-Like App

By Ananya Gairola

March 12, 11:38 PM

Twitter Chief Elon Musk mocked Meta Platforms Inc. (NASDAQ:META) CEO Mark Zuckerberg for considering launc

$DOGE

Humana Blames Medicare Advantage As Stock Falls After Larger Than Expected Quarterly Loss, Grim Outlook

By Vandana Singh

January 25, 9:22 AM

Humana faces challenges as Q4 2023 earnings disappoint. Adjusted EPS loss at $(0.11), revenue at $25.73 billion.

authID Momentum Drives 300% Increase In Quarter Over Quarter Sales; New Sales Team Secures Over $1M In Aggregate BARR

By Benzinga Newsdesk

October 4, 8:10 AM

New sales team secures over $1 Million in aggregate BARR DENVER, Oct. 04, 2023 (GLOBE NEWSWIRE) -- authID® (NASDAQ:AUID), a leading provider of innovative biometric identity verification and

AUID

News

ENHERTU Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers

By Happy Mohamed

August 31, 8:03 AM

Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer ENHERTU has now been granted seven

AZN

Needham Maintains Buy on NAPCO Security Techs, Raises Price Target to $34

Related Posts

‘Copy Cat:’ Elon Musk Taunts Mark Zuckerberg For Reportedly Planning Twitter-Like App

Humana Blames Medicare Advantage As Stock Falls After Larger Than Expected Quarterly Loss, Grim Outlook

authID Momentum Drives 300% Increase In Quarter Over Quarter Sales; New Sales Team Secures Over $1M In Aggregate BARR

ENHERTU Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers